Sign in

    Destiny Hance

    Research Analyst at Ladenburg Thalmann

    Destiny Hance is the Associate Director of Research at Ladenburg Thalmann & Co. Inc., specializing in healthcare and life sciences equity research as well as coverage of real estate investment trusts, including The Macerich Company and Simon Property Group. With a recent 100% success rate and an average return of 5.45% on rated stocks, she delivers detailed fundamental analysis and actionable stock recommendations. Hance began her career at Ladenburg Thalmann as an intern in 2017, progressing through roles as Associate, Senior Associate, Vice President, and now Associate Director, while also holding an MBA from the University of Florida. She is FINRA-registered with Series 7, 86, and 87 licenses and is recognized for leading research initiatives, overseeing a team, and conducting advanced company and sector analysis.

    Destiny Hance's questions to ARTIVION (AORT) leadership

    Destiny Hance's questions to ARTIVION (AORT) leadership • Q2 2025

    Question

    Destiny Hance from Ladenburg Thalmann inquired about the current pricing trends and the company's pricing power in the market.

    Answer

    CFO Lance Berry responded that Artivion continues to experience a stable pricing environment. Due to the life-saving nature of its products, the company has consistently been able to implement modest, inflationary price increases without significant pressure. He noted that current growth is primarily volume-driven rather than from any exceptionally large price hikes.

    Ask Fintool Equity Research AI